Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care. Our pipeline of innovative, non-invasive technologies, such as our APEX technology, will empower researchers and clinicians with unparalleled insights not available from current tests.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $14M
Founded date: 2021
Investors 5
| Date | Name | Website |
| - | ARCH Ventu... | archventur... |
| - | S32 | s32.com |
| - | Rivas Capi... | rivascap.c... |
| - | DNS Capita... | dnscap.com |
| 17.05.2024 | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.10.2024 | - | $14M | - |
Mentions in press and media 5
| Date | Title | Description |
| 22.10.2024 | Sunbird Bio: $14 Million Closed To Advance Blood-Based Diagnostic Platform In Alzheimer’s Disease | Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve the diagnosis and treatment of neurological disorders and early-stage cancer, announced the closing of a $14 million financing round backed by t... |
| 16.10.2024 | Sunbird Bio Raises Additional $14M in Funding | Sunbird Bio, a Cambridge, MA-based biotechnology company developing proprietary blood-based technologies, raised additional $14M in funding. The round was led by Eli Lilly and Company and EDBI, as well as continued participation from existi... |
| 16.10.2024 | Sunbird Bio Secures $14 Million | CAMBRIDGE, MA, Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced the closing of a $14 million financing round... |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build. ClavystBio has committed US$220 million to date in investments to launch global ... |
| - | Sunbird Bio | “Sunbird Bio, a biotech company, is developing protein-based diagnostic tests that empower diagnosis and treatment of Alzheimer's disease, neurological disorders, and early-stage cancer.” |